NasdaqGS - Nasdaq Real Time Price USD
Ultragenyx Pharmaceutical Inc. (RARE)
35.86
+0.25
+(0.70%)
As of 1:14:05 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 8 | 10 |
| Avg. Estimate | -1.32 | -1.31 | -5.31 | -3.32 |
| Low Estimate | -1.41 | -1.51 | -5.78 | -5.12 |
| High Estimate | -1.11 | -1.01 | -4.51 | -0.22 |
| Year Ago EPS | -1.52 | -1.4 | -6.29 | -5.31 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 16 | 16 | 19 | 19 |
| Avg. Estimate | 161.3M | 164.06M | 649.73M | 841.8M |
| Low Estimate | 148M | 150M | 589M | 698.47M |
| High Estimate | 174M | 174.43M | 669.35M | 1.02B |
| Year Ago Sales | 147.03M | 139.49M | 560.23M | 649.73M |
| Sales Growth (year/est) | 9.71% | 17.61% | 15.98% | 29.56% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -1.63 | -1.47 | -1.27 | -1.64 |
| EPS Actual | -1.52 | -1.4 | -1.39 | -1.57 |
| Difference | 0.11 | 0.07 | -0.12 | 0.07 |
| Surprise % | 6.90% | 4.96% | -9.45% | 4.44% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -1.32 | -1.31 | -5.31 | -3.32 |
| 7 Days Ago | -1.38 | -1.32 | -5.43 | -3.61 |
| 30 Days Ago | -1.38 | -1.32 | -5.43 | -3.61 |
| 60 Days Ago | -1.38 | -1.32 | -5.43 | -3.6 |
| 90 Days Ago | -1.25 | -1.23 | -5.07 | -3.5 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | 1 | 1 |
| Up Last 30 Days | -- | 1 | 1 | 1 |
| Down Last 7 Days | 1 | -- | -- | -- |
| Down Last 30 Days | 1 | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| RARE | 13.24% | 6.16% | 15.60% | 37.56% |
| S&P 500 | 13.32% | 2.67% | 7.78% | 13.75% |
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 10/22/2024 |
| Maintains | TD Cowen: Buy to Buy | 10/21/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 10/1/2024 |
| Reiterates | RBC Capital: Outperform to Outperform | 9/26/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/20/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/16/2024 |
Related Tickers
MREO Mereo BioPharma Group plc
2.2350
-0.22%
AGIO Agios Pharmaceuticals, Inc.
29.47
+0.99%
PTCT PTC Therapeutics, Inc.
46.76
+1.63%
KRYS Krystal Biotech, Inc.
131.88
+0.98%
BPMC Blueprint Medicines Corporation
101.00
-0.68%
RGNX REGENXBIO Inc.
9.28
+4.33%
IONS Ionis Pharmaceuticals, Inc.
33.73
+0.51%
BMRN BioMarin Pharmaceutical Inc.
59.15
-0.20%
CRNX Crinetics Pharmaceuticals, Inc.
30.99
-0.80%
FOLD Amicus Therapeutics, Inc.
6.43
0.00%